PTC Therapeutics plans USD 500 million convertible senior notes offering due 2031

By Public Technologies
  • PTC Therapeutics plans a private offering of USD 500 million Convertible Senior Notes due 2031, with an option for USD 50 million more.
  • Net proceeds earmarked to repurchase or repay its 1.5% Convertible Senior Notes due 2026.
  • Also targets about USD 50 million of common stock repurchases alongside the offering.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606150700PR_NEWS_USPR_____NY83232) on June 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.